Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$3.38
-0.9%
$3.45
$3.07
$6.66
$209.18M0.53603,595 shs664,943 shs
Alector, Inc. stock logo
ALEC
Alector
$1.63
-0.6%
$2.25
$1.09
$3.40
$182.08M0.61761,114 shs439,473 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$0.69
-3.0%
$0.82
$0.66
$2.10
$169.54M1.47402,283 shs355,538 shs
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
$1.60
-11.1%
$0.85
$0.55
$10.00
$42.46M0.94.22 million shs457,874 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+0.89%-6.32%0.00%-3.67%-40.38%
Alector, Inc. stock logo
ALEC
Alector
+0.31%-20.77%-21.90%-31.09%+10.07%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
+0.59%-17.28%-7.25%-38.43%-26.17%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-11.76%+9.09%+187.49%+108.84%-64.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$3.38
-0.9%
$3.45
$3.07
$6.66
$209.18M0.53603,595 shs664,943 shs
Alector, Inc. stock logo
ALEC
Alector
$1.63
-0.6%
$2.25
$1.09
$3.40
$182.08M0.61761,114 shs439,473 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$0.69
-3.0%
$0.82
$0.66
$2.10
$169.54M1.47402,283 shs355,538 shs
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
$1.60
-11.1%
$0.85
$0.55
$10.00
$42.46M0.94.22 million shs457,874 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+0.89%-6.32%0.00%-3.67%-40.38%
Alector, Inc. stock logo
ALEC
Alector
+0.31%-20.77%-21.90%-31.09%+10.07%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
+0.59%-17.28%-7.25%-38.43%-26.17%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-11.76%+9.09%+187.49%+108.84%-64.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
2.00
HoldN/AN/A
Alector, Inc. stock logo
ALEC
Alector
2.13
Hold$3.63122.39% Upside
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
2.00
Hold$16.502,282.33% Upside
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest GNTA, ACB, ENLV, and ALEC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
Alector, Inc. stock logo
ALEC
Alector
Reiterated RatingSell (E+)
5/4/2026
Alector, Inc. stock logo
ALEC
Alector
Reiterated RatingUnderweight$2.00
5/1/2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
UpgradeSell (E+)Sell (D-)
4/15/2026
Alector, Inc. stock logo
ALEC
Alector
UpgradeNeutralOverweight
4/7/2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
Boost Price TargetBuy$13.00 ➝ $20.00
3/27/2026
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
Reiterated RatingSell (E+)
3/10/2026
Alector, Inc. stock logo
ALEC
Alector
UpgradeNeutralBuy$6.00
(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M0.84$0.61 per share5.58$7.78 per share0.43
Alector, Inc. stock logo
ALEC
Alector
$21.05M8.60N/AN/A$0.28 per share5.82
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$8.15 per shareN/A
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/AN/AN/AN/A$1.29 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M-$1.08N/AN/AN/A-23.46%-0.04%-0.03%6/11/2026 (Estimated)
Alector, Inc. stock logo
ALEC
Alector
-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%8/24/2026 (Estimated)
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-$7.39MN/AN/AN/AN/AN/AN/AN/AN/A

Latest GNTA, ACB, ENLV, and ALEC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/11/2026Q4 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$0.07N/AN/AN/A$54.42 millionN/A
5/7/2026Q1 2026
Alector, Inc. stock logo
ALEC
Alector
-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million
3/31/2026Q4 2025
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-$0.3641-$0.0750+$0.2891-$0.0750N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.06
3.06
1.48
Alector, Inc. stock logo
ALEC
Alector
0.80
5.25
5.25
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
193.24
193.24
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
0.35
14.16
14.16

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Alector, Inc. stock logo
ALEC
Alector
85.83%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
15.13%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Alector, Inc. stock logo
ALEC
Alector
8.30%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
28.99%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13061.34 million61.34 millionOptionable
Alector, Inc. stock logo
ALEC
Alector
270111.03 million101.81 millionOptionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
70237.38 million208.23 millionOptionable
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
723.59 million16.75 millionNot Optionable

Recent News About These Companies

Genenta signs Definitive Agreements with Sophia High Tech
Genenta Science Provides Update on CEO Ownership

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$3.38 -0.03 (-0.88%)
Closing price 04:00 PM Eastern
Extended Trading
$3.40 +0.02 (+0.56%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Alector stock logo

Alector NASDAQ:ALEC

$1.63 -0.01 (-0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$1.63 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$0.69 -0.02 (-3.02%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 +0.00 (+0.64%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Genenta Science stock logo

Genenta Science NASDAQ:GNTA

$1.60 -0.20 (-11.11%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 +0.14 (+8.75%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.